<DOC>
	<DOC>NCT00738153</DOC>
	<brief_summary>This observational study is conducted in Africa. The aim of this observational study is to evaluate the efficacy and the incidence of serious adverse drug reactions while using insulin Levemir® under normal clinical practice conditions.</brief_summary>
	<brief_title>An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Any subject with Type 1 or Type 2 diabetes mellitus is eligible for the study, including newlydiagnosed subjects who have never received insulin or an insulin analogue before. The selection of the subjects will be at the discretion of the individual physician Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit Currently being treated with insulin detemir Previously enrolled in this study Hypersensitivity to insulin detemir or to any of the excipients Pregnancy, breastfeeding, the intention to become pregnant or judged not to be using adequate contraceptive measures.</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>